Immunogenicity of Vi capsular polysaccharide vaccine evaluated for three years in Korea.

Y. R. Kim; J. H. Yoo; J. K. Hur; J. H. Kang; W. S. Shin; M. W. Kang

doi:10.3346/jkms.1995.10.5.314

Immunogenicity of Vi capsular polysaccharide vaccine evaluated for three years in Korea.

Y. R. Kim
, J. H. Yoo
, J. K. Hur
, J. H. Kang
, W. S. Shin
, M. W. Kang

Division of Infectious Disease

The Catholic University of Korea, College of Medicine

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

The immunogenicity of a single dose of Salmonella typhi(S.typhi) Vi capsular polysaccharide(CPS) vaccine was evaluated before, and at 1, 3, 12, and 36 months after vaccination. Eighty-five adults(20-28 years of age) and sixty-four children(8-16 years of age) received a single dose of 25 micrograms Vi CPS vaccine intramuscularly, and antibody titers to Vi CPS were measured by passive hemagglutination. Of 149 vaccinees, 138(92.6%) showed seroconversion at 1 month after vaccination, and then 138 out of 141(97.9%) did at 3 months. Of 137 vaccinees, 116(84.7%) maintained a persistent rise in Vi antibody titer 12 months after vaccination, and 55 out of 100(55.0%) had a 4-fold or greater rise at 36 months. No significant adverse reactions were observed. Booster injection may be needed 3-5 years after vaccination.

Original language	English
Pages (from-to)	314-317
Number of pages	4
Journal	Journal of Korean Medical Science
Volume	10
Issue number	5
DOIs	https://doi.org/10.3346/jkms.1995.10.5.314
State	Published - Oct 1995

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.3346/jkms.1995.10.5.314

Cite this

@article{2fd264fe191c4158bc7805c95e093833,

title = "Immunogenicity of Vi capsular polysaccharide vaccine evaluated for three years in Korea.",

abstract = "The immunogenicity of a single dose of Salmonella typhi(S.typhi) Vi capsular polysaccharide(CPS) vaccine was evaluated before, and at 1, 3, 12, and 36 months after vaccination. Eighty-five adults(20-28 years of age) and sixty-four children(8-16 years of age) received a single dose of 25 micrograms Vi CPS vaccine intramuscularly, and antibody titers to Vi CPS were measured by passive hemagglutination. Of 149 vaccinees, 138(92.6\%) showed seroconversion at 1 month after vaccination, and then 138 out of 141(97.9\%) did at 3 months. Of 137 vaccinees, 116(84.7\%) maintained a persistent rise in Vi antibody titer 12 months after vaccination, and 55 out of 100(55.0\%) had a 4-fold or greater rise at 36 months. No significant adverse reactions were observed. Booster injection may be needed 3-5 years after vaccination.",

author = "Kim, \{Y. R.\} and Yoo, \{J. H.\} and Hur, \{J. K.\} and Kang, \{J. H.\} and Shin, \{W. S.\} and Kang, \{M. W.\}",

year = "1995",

month = oct,

doi = "10.3346/jkms.1995.10.5.314",

language = "English",

volume = "10",

pages = "314--317",

journal = "Journal of Korean Medical Science",

issn = "1011-8934",

publisher = "Korean Academy of Medical Science",

number = "5",

}

TY - JOUR

T1 - Immunogenicity of Vi capsular polysaccharide vaccine evaluated for three years in Korea.

AU - Kim, Y. R.

AU - Yoo, J. H.

AU - Hur, J. K.

AU - Kang, J. H.

AU - Shin, W. S.

AU - Kang, M. W.

PY - 1995/10

Y1 - 1995/10

N2 - The immunogenicity of a single dose of Salmonella typhi(S.typhi) Vi capsular polysaccharide(CPS) vaccine was evaluated before, and at 1, 3, 12, and 36 months after vaccination. Eighty-five adults(20-28 years of age) and sixty-four children(8-16 years of age) received a single dose of 25 micrograms Vi CPS vaccine intramuscularly, and antibody titers to Vi CPS were measured by passive hemagglutination. Of 149 vaccinees, 138(92.6%) showed seroconversion at 1 month after vaccination, and then 138 out of 141(97.9%) did at 3 months. Of 137 vaccinees, 116(84.7%) maintained a persistent rise in Vi antibody titer 12 months after vaccination, and 55 out of 100(55.0%) had a 4-fold or greater rise at 36 months. No significant adverse reactions were observed. Booster injection may be needed 3-5 years after vaccination.

AB - The immunogenicity of a single dose of Salmonella typhi(S.typhi) Vi capsular polysaccharide(CPS) vaccine was evaluated before, and at 1, 3, 12, and 36 months after vaccination. Eighty-five adults(20-28 years of age) and sixty-four children(8-16 years of age) received a single dose of 25 micrograms Vi CPS vaccine intramuscularly, and antibody titers to Vi CPS were measured by passive hemagglutination. Of 149 vaccinees, 138(92.6%) showed seroconversion at 1 month after vaccination, and then 138 out of 141(97.9%) did at 3 months. Of 137 vaccinees, 116(84.7%) maintained a persistent rise in Vi antibody titer 12 months after vaccination, and 55 out of 100(55.0%) had a 4-fold or greater rise at 36 months. No significant adverse reactions were observed. Booster injection may be needed 3-5 years after vaccination.

UR - https://www.scopus.com/pages/publications/0029383738

U2 - 10.3346/jkms.1995.10.5.314

DO - 10.3346/jkms.1995.10.5.314

M3 - Article

C2 - 8750055

AN - SCOPUS:0029383738

SN - 1011-8934

VL - 10

SP - 314

EP - 317

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

IS - 5

ER -

Immunogenicity of Vi capsular polysaccharide vaccine evaluated for three years in Korea.

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this